Last reviewed · How we verify
NCT03981705
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
trial testing Standard Trimodality Breast Imaging in TN ER-/PR-/HER2- Breast Cancer in 8 participants. Completed in 26 November 2024.
19 February 2024
Quick facts
| Lead sponsor | Masonic Cancer Center, University of Minnesota |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 8 August 2019 |
| Primary completion | 19 February 2024 |
| Estimated completion | 26 November 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Standard Trimodality Breast Imaging
Conditions studied
- TN ER-/PR-/HER2- Breast Cancer — all drugs for TN ER-/PR-/HER2- Breast Cancer →
- Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
- HER2-positive Breast Cancer — all drugs for HER2-positive Breast Cancer →
- ERany/PRany/HER2+ Breast Cancer — all drugs for ERany/PRany/HER2+ Breast Cancer →
Sponsor
Masonic Cancer Center, University of Minnesota
Who can join
18 and older, female only, with TN ER-/PR-/HER2- Breast Cancer or Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03981705
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Masonic Cancer Center, University of Minnesota trials
Trials by the same sponsor.
- NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies · NA · not yet recruiting
- NCT06584929 — Rural Smoking Cessation · NA · not yet recruiting
- NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect · NA · recruiting
- NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
- NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03981705 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
- Last refreshed: 27 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03981705.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing